| Home > Publications Database > Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial > Access to Fulltext |
DZNE-2023-01159
|
|||||||
| version 1 |
| ||||||